Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2013 Aug:54 Suppl 4:3-12.
doi: 10.1111/epi.12294.

Development of new treatment approaches for epilepsy: unmet needs and opportunities

Jacqueline A French  1 , H Steve White, Henrik Klitgaard, Gregory L Holmes, Michael D Privitera, Andrew J Cole, Ellinor Quay, Samuel Wiebe, Dieter Schmidt, Roger J Porter, Alexis Arzimanoglou, Eugen Trinka, Emilio Perucca
Affiliations
Free article
Review

Development of new treatment approaches for epilepsy: unmet needs and opportunities

Jacqueline A French et al. Epilepsia. 2013 Aug.
Free article

Abstract

A working group was created to address clinical "gaps to care" as well as opportunities for development of new treatment approaches for epilepsy. The working group primarily comprised clinicians, trialists, and pharmacologists. The group identified a need for better animal models for both efficacy and tolerability, and noted that animal models for potential disease-modifying or antiepileptogenic effect should mirror conditions in human trials. For antiseizure drugs (ASDs), current animal models have not been validated with respect to their relationship to efficacy in common epilepsy syndromes. The group performed an "expert opinion" survey of perceived efficacy of the available ASDs, and identified a specific unmet need for ASDs to treat tonic-atonic and myoclonic seizures. No correlation has as yet been demonstrated between animal models of tolerability and adverse effects (AEs), versus tolerability in humans. There is a clear opportunity for improved therapies in relation to dose-related AEs. The group identified common and rare epilepsy syndromes that could represent opportunities for clinical trials. They identified opportunities for antiepileptogenic (AEG) therapies in both adults and children, acknowledging that the presence of a biomarker would substantially improve the chances of a successful trial. However, the group acknowledged that disease-modifying therapies (given after the first seizure or after the development of epilepsy) would be easier to study than AEG therapies.

Keywords: Animal models; Antiepileptogenic therapy; Antiseizure therapy; Epilepsy syndromes.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

MeSH terms